NO20052149L - Polynukleotidvaksine omfattende sekvens som koder for hepatitt C-virus protein. - Google Patents

Polynukleotidvaksine omfattende sekvens som koder for hepatitt C-virus protein.

Info

Publication number
NO20052149L
NO20052149L NO20052149A NO20052149A NO20052149L NO 20052149 L NO20052149 L NO 20052149L NO 20052149 A NO20052149 A NO 20052149A NO 20052149 A NO20052149 A NO 20052149A NO 20052149 L NO20052149 L NO 20052149L
Authority
NO
Norway
Prior art keywords
hcv
sequence encoding
protein
polynucleotide sequence
virus protein
Prior art date
Application number
NO20052149A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052149D0 (no
Inventor
Paul A Hamblin
Sara Brett
Louise Ogilvie
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20052149D0 publication Critical patent/NO20052149D0/no
Publication of NO20052149L publication Critical patent/NO20052149L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
NO20052149A 2002-11-15 2005-05-02 Polynukleotidvaksine omfattende sekvens som koder for hepatitt C-virus protein. NO20052149L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine
PCT/EP2003/012793 WO2004046175A1 (fr) 2002-11-15 2003-11-13 Vaccin contre l'hepatite c

Publications (2)

Publication Number Publication Date
NO20052149D0 NO20052149D0 (no) 2005-05-02
NO20052149L true NO20052149L (no) 2005-07-11

Family

ID=9947928

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20052149A NO20052149L (no) 2002-11-15 2005-05-02 Polynukleotidvaksine omfattende sekvens som koder for hepatitt C-virus protein.
NO20052136A NO20052136L (no) 2002-11-15 2005-05-02 Vaksine mot Hepatitt C-virus (HCV).

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20052136A NO20052136L (no) 2002-11-15 2005-05-02 Vaksine mot Hepatitt C-virus (HCV).

Country Status (21)

Country Link
US (4) US20060246090A1 (fr)
EP (2) EP1560845A1 (fr)
JP (2) JP2006518331A (fr)
KR (2) KR20050085009A (fr)
CN (2) CN1738834A (fr)
AR (1) AR041964A1 (fr)
AU (2) AU2003288084A1 (fr)
BR (2) BR0316244A (fr)
CA (2) CA2504654A1 (fr)
CO (1) CO5700833A2 (fr)
GB (1) GB0226722D0 (fr)
IS (2) IS7830A (fr)
MA (2) MA27699A1 (fr)
MX (2) MXPA05005203A (fr)
NO (2) NO20052149L (fr)
NZ (2) NZ539999A (fr)
PL (2) PL376967A1 (fr)
RU (2) RU2363492C2 (fr)
TW (1) TW200502246A (fr)
WO (2) WO2004046175A1 (fr)
ZA (2) ZA200503802B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP2460533A3 (fr) * 2004-10-18 2014-01-08 Globeimmune, Inc. Moyens thérapeutiques à base de levure contre l'infection par hépatite C chronique
ES2551113T3 (es) * 2006-01-04 2015-11-16 Glaxosmithkline Biologicals S.A. Proteína E1E2 del VHC adyuvantada con MF59 más vector de alfavirus que codifica E1E2 del VHC para provocar linfocitos T específicos del VHC
US8211444B2 (en) * 2006-03-09 2012-07-03 Transgene S.A. Hepatitis C virus non structural fusion protein
AU2007345682B2 (en) * 2006-07-27 2013-07-18 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
JP5683811B2 (ja) * 2006-07-27 2015-03-11 タケダ ヴァクシーンズ， インコーポレイテッド キメラインフルエンザウイルス様粒子
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
WO2009022236A2 (fr) 2007-08-16 2009-02-19 Tripep Ab Plate-forme immunogène
RU2370776C2 (ru) * 2007-11-08 2009-10-20 Общество с ограниченной ответственностью "Диагностические Центры "Алкор Био" Набор антигенов для раздельного выявления антител к структурным и неструктурным белкам вируса гепатита с
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
CA2722423A1 (fr) * 2008-04-22 2009-10-29 Rutgers, The State University Compositions de produit de construction e2 de vhc et procedes correspondants
WO2010011870A2 (fr) * 2008-07-24 2010-01-28 Anza Therapeutics, Inc. Compositions et procédés de traitement de l'hépatite c
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
EP2496609A4 (fr) 2009-11-03 2013-05-08 Ligocyte Pharmaceuticals Inc Particules de type viral (vlp) chimériques à base de gag de polypeptide rsv-f et de lentivirus ou alpharétrovirus
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
JP2016513115A (ja) 2013-02-21 2016-05-12 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド ワクチン組成物
CN119504957B (zh) * 2025-01-16 2025-04-25 中山大学 一种佐剂及其在制备疫苗中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
BR8807310A (pt) * 1987-11-18 1990-03-13 Chiron Corp Polinucleotidio,polinucleotidio recombinante,vetor recombinante,celula hospedeira,sistema de expressao recombinante,celula transformada,polipeptidio,hcv,preparacao de polipeptidio,polipeptidio de hcv,polipeptidio purificado,polipeptidio recombinante,polipeptidio de fusao,anticorpo monoclonal,preparacao purificada de anticorpos policlonais,particula,sonda de polinucleotidio,kit anticorpo para epetopo de hcv,metodo para producao de polipeptidio,metodo para deteccao de acidos nucleicos de hcv,imunoensaio para detectar antigeno de hcv,imunoensaio para detectar anticorpos dirigidos contra antigeno de hcv,vacina para tratamento de infeccao de hcv,celula,celula infectada com hcv,metodo para producao de anticorpos para hcv e metodo para isolar cdna derivado do genoma de um agente infeccioso nao identificado
CA2070952A1 (fr) * 1991-06-11 1992-12-12 Makoto Seki Gene du virus de l'hepatite c ou fragment dudit gene, polypeptide code par le gene
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
DE69533167D1 (de) * 1994-10-05 2004-07-22 Apollon Inc Impfstoffe gegen den hepatitis b und c virus
IL118364A0 (en) * 1995-05-22 1996-09-12 Bionova Corp A hepatitis C virus-derived composition methods for the preparation thereof and assays for the detection of hepatitis C virus
AU717542B2 (en) * 1996-06-11 2000-03-30 Merck & Co., Inc. Synthetic hepatitis C genes
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
EP1200465A1 (fr) * 1999-07-09 2002-05-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by The Secretary, Department of Health and Human Services Epitopes antigeniques et polypeptides de mosaique des proteines du virus de l'hepatite c
AU1236801A (en) * 1999-10-27 2001-05-08 Chiron Corporation Activation of hcv-specific t cells
CN101684146A (zh) * 1999-11-24 2010-03-31 诺华疫苗和诊断公司 新颖的hcv非结构多肽
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Also Published As

Publication number Publication date
RU2005113691A (ru) 2006-01-27
NO20052149D0 (no) 2005-05-02
BR0316244A (pt) 2005-10-04
US20090232847A1 (en) 2009-09-17
CN1738833A (zh) 2006-02-22
MXPA05005202A (es) 2006-01-27
ZA200503802B (en) 2006-08-30
AU2003288072A1 (en) 2004-06-15
AR041964A1 (es) 2005-06-01
EP1560844A1 (fr) 2005-08-10
WO2004046176A1 (fr) 2004-06-03
US20060246090A1 (en) 2006-11-02
TW200502246A (en) 2005-01-16
US20090104231A1 (en) 2009-04-23
IS7831A (is) 2005-04-28
GB0226722D0 (en) 2002-12-24
CN1738834A (zh) 2006-02-22
KR20050085009A (ko) 2005-08-29
PL376882A1 (pl) 2006-01-09
RU2363492C2 (ru) 2009-08-10
AU2003288084A1 (en) 2004-06-15
MXPA05005203A (es) 2006-01-27
NZ539999A (en) 2008-03-28
US20060135451A1 (en) 2006-06-22
NO20052136D0 (no) 2005-05-02
WO2004046175A1 (fr) 2004-06-03
KR20050085010A (ko) 2005-08-29
RU2005113692A (ru) 2006-01-27
CA2504654A1 (fr) 2004-06-03
BR0316291A (pt) 2005-10-11
EP1560845A1 (fr) 2005-08-10
MA27699A1 (fr) 2006-01-02
RU2323744C2 (ru) 2008-05-10
NZ539998A (en) 2008-04-30
JP2006524181A (ja) 2006-10-26
NO20052136L (no) 2005-07-11
PL376967A1 (pl) 2006-01-23
IS7830A (is) 2005-04-28
CO5700833A2 (es) 2006-11-30
ZA200503803B (en) 2006-08-30
MA27700A1 (fr) 2006-01-02
JP2006518331A (ja) 2006-08-10
CA2504715A1 (fr) 2004-06-03

Similar Documents

Publication Publication Date Title
Gawish et al. ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF-and IFNγ-driven immunopathology
Patterson et al. Epidemiology and pathogenesis of Bolivian hemorrhagic fever
MXPA05005202A (es) Vacuna.
EA200401405A1 (ru) Модифицированный осповакцинный вирус анкара для вакцинации новорожденных
NO20054608L (no) Influensavirusvaksine
ATE499442T1 (de) Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz
PT1335987E (pt) Variante do virus vacina modificado ancara
Darweesh et al. Characterization of the cytopathic BVDV strains isolated from 13 mucosal disease cases arising in a cattle herd
BR112022016992A2 (pt) Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
MX2023000041A (es) Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus.
WO2021257510A3 (fr) Vaccin contre le virus de la rougeole exprimant une ou plusieurs protéines du sars-cov-2
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
Sinha et al. Virus-encoded complement regulators: current status
EP1613345A4 (fr) Compositions contenant un virus syncytial respiratoire de la souche 9320 du sous-groupe b, et procedes associes
NO20062948L (no) Promotere for ekspresjon i modifisert vaccinia-virus Ankara
Vilček et al. Cellular insertions in the NS2-3 genome region of cytopathic bovine viral diarrhoea virus (BVDV) isolates
EA201500837A1 (ru) Парвовирус свиней 5в, способы применения и вакцина
ATE556136T1 (de) Nichtstrukturelles hcv-fusionsprotein
Lattwein et al. Pestivirus virion morphogenesis in the absence of uncleaved nonstructural protein 2-3
Mósena et al. Genomic and antigenic relationships between two ‘HoBi’-like strains and other members of the Pestivirus genus
PH12020551944A1 (en) Reverse peptide vaccine
NO20081541L (no) Ny sjo-lus vaksine
Mazhar et al. Severe acute respiratory syndrome (Saras Covid-2): a comprehensive review
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application